Trial · NCT04576988
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 | Sotatercept Plus Background PAH Therapy (DBPC Period) | 34.4 | Full Range 32.5 to 35.5 | meters | |
| Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 | Placebo Plus Background PAH Therapy (DBPC Period) | 1.0 | Full Range -1.0 to 5.0 | meters | |
| Number of Participants Who Experienced an Adverse Event (AE) | Sotatercept Plus Background PAH Therapy (DBPC Period) | 138 | Participants | ||
| Number of Participants Who Experienced an Adverse Event (AE) | Placebo Plus Background PAH Therapy (DBPC Period) | 140 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE | Sotatercept Plus Background PAH Therapy (DBPC Period) | 3 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE | Placebo Plus Background PAH Therapy (DBPC Period) | 10 | Participants | ||
| Change From Baseline in the Percentage of Participants Achieving Multicomponent Improvement at Week 24 | Sotatercept Plus Background PAH Therapy (DBPC Period) | 38.9 | Percent change | ||
| Change From Baseline in the Percentage of Participants Achieving Multicomponent Improvement at Week 24 | Placebo Plus Background PAH Therapy (DBPC Period) | 10.1 | Percent change | ||
| Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24 | Sotatercept Plus Background PAH Therapy (DBPC Period) | -165.1 | Full Range -184.0 to -152.0 | dynes*sec/cm^5 | |
| Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24 | Placebo Plus Background PAH Therapy (DBPC Period) | 32.8 | Full Range 24.0 to 40.0 | dynes*sec/cm^5 | |
| Change From Baseline in NT-proBNP Levels at Week 24 | Sotatercept Plus Background PAH Therapy (DBPC Period) | -230.3 | Full Range -236.0 to -223.0 | pg/mL | |
| Change From Baseline in NT-proBNP Levels at Week 24 | Placebo Plus Background PAH Therapy (DPBC Period) | 58.6 | Full Range 44.0 to 73.0 | pg/mL | |
| Change From Baseline in the Percentage of Participants Who Improve in WHO FC at Week 24 | Sotatercept Plus Background PAH Therapy (DBPC Period) | 29.4 | Percent change | ||
| Change From Baseline in the Percentage of Participants Who Improve in WHO FC at Week 24 | Placebo Plus Background PAH Therapy (DBPC Period) | 13.8 | Percent change | ||
| Time to Death or the First Occurrence of Clinical Worsening Event | Sotatercept Plus Background PAH Therapy | NA | Standard Deviation NA | Weeks | |
| Time to Death or the First Occurrence of Clinical Worsening Event | Placebo Plus Background PAH Therapy | NA | Standard Deviation NA | Weeks | |
| Change From Baseline in Percentage of Participants Who Maintain or Achieve a Low Risk Score Using the Simplified French Risk Score Calculator at Week 24 | Sotatercept Plus Background PAH Therapy (DBPC Period) | 39.5 | Percent Change | ||
| Change From Baseline in Percentage of Participants Who Maintain or Achieve a Low Risk Score Using the Simplified French Risk Score Calculator at Week 24 | Placebo Plus Background PAH Therapy (DBPC Period) | 18.2 | Percent Change | ||
| Change From Baseline in the Physical Impacts Domain Score of Pulmonary Arterial Hypertension - Symptoms and Impact (PAH-SYMPACT®) at Week 24 | Sotatercept Plus Background PAH Therapy (DBPC Period) | -0.13 | Full Range -0.15 to 0.00 | Score on a scale | |
| Change From Baseline in the Physical Impacts Domain Score of Pulmonary Arterial Hypertension - Symptoms and Impact (PAH-SYMPACT®) at Week 24 | Placebo Plus Background PAH Therapy (DBPC Period) | 0.01 | Full Range 0.00 to 0.14 | Score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04576988/results